

## DAFTAR PUSTAKA

- Amaravadi, R.K., Lippincott-Schwartz, J., Yin, X.M., Weiss, W.A., Takebe, N., Timmer, W., *et al.* (2011). Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. *Clin. Cancer Res.* 17:654-66.
- American Cancer Society. (2010). Breast Cancer Staging 7th Edition. *American Joint Committee on Cancer.* pp.1-2. Diakses dari <http://www.cancerstaging.org>.
- Bialik, S. & Kimchi, A. (2008). Autophagy and Tumor Suppression: Recent Advances in Understanding the Link between Autophagic Cell Death Pathways and Tumor Development. *Adv. Exp. Med. Biol.* pp.177-200.
- Boenisch, T., Kumar, G. L., Rudbeck, L. (2009). *Immunohistochemical Staining Method.* Fifth Edition. Dako North America: California.
- Chen, N. & Karantza-Wadsworth, V. (2009). Role and Regulation of Autophagy in Cancer. *Biochim Biophys Acta.* 1793.1516-23
- Chen, S., Rehman, S.K., Zhang, W., Wen, A., Yao, L., Zhang, J. (2010). Autophagy is a Therapeutic Target in Anticancer Drug Resistance. *Biochim Biophys Acta.* 1806.220-9
- Clark, G.J. & Der, C.J. (1995). Aberrant Function of the Ras Signal Transduction Pathway in Human Breast Cancer. *Breast Cancer Res. Treat.* 35(1):133-4
- Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., *et al.* (2006). Autophagy Promotes Tumor Cell Survival and Restricts Necrosis, Inflammation, and Tumorigenesis. *Cancer cell.* 10: 51-64.
- Elgendy, M., Sheridan, C., Brumatti, G., Martin, S.J. (2011). Oncogenic Ras-induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival. *Mol. Cell.* 42: 23-35
- Faivre, S., Kroemer, G., Raymond, E. (2006). Current Development of mTOR Inhibitors as Anticancer Agents. *Nat. Rev. Drug Discov.* 5. pp.671-688.
- Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., *et al.* (2007). The Regulation of AMPK beta1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways. *Cancer Res.* 67: 3043-3053.

- Gera, J.F., Mellinshoff, I.K., Shi, Y., Rettig, M.B., Tran, C., Hsu, J.H., *et al.* (2004). AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and C-myc Expression. *J. Biol. Chem.* 279:2737–2746.
- Glick, D., Barth, S., Macleod, K.F. (2010). Autophagy : Cellular and Molecular Mechanisms. *J. Pathol.* 221(1). pp.3–12.
- Balaburski, G. M., Hontz, R. D., Murphy, M. E. (2010). p53 and ARF: Unexpected Players in Autophagy. *Trends in Cell Biology.* 20(6). pp. 363–369.
- Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, *et al.* (2011). Activated Ras Requires Autophagy to Maintain Oxidative Metabolism and Tumorigenesis. *Genes & Development.* 25(5). pp.460–470.
- Guertin, D.A. & Sabatini, D.M. (2007). Defining the Role of mTOR in Cancer. *Cancer Cell.* 12(1). pp. 9–22.
- Honma, N., Horii, R., Ito, Y., Saji, S., Younes, M., Iwase, T., *et al.* (2015). Differences in Clinical Importance of Bcl-2 in Breast Cancer According to Hormone Receptors Status or Adjuvant Endocrine Therapy. *BMC Cancer.* 15:698.
- Hu, Y., Jahangiri, A., DeLay, M., Aghi, M. (2012). Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy. *Cancer Research.* 72(17). pp.4294-4299.
- Kasper, D. L., Fauci, A. S., Longo, D. L., Braunwald, E., Hauser, S. L., Jameson, J. L. (2005). *Harrison's Principles of Internal Medicine.* 16rd ed. Los Angeles: McGraw-Hills.
- Kim, J., Otto, N., Conti, C.J., Gimenz-Conti, B., Walker, C.L. (2012). Immunohistochemical Analysis of mTOR Activity in Tissues. *Methods Mol. Biol.* 821.
- Kimmelman, A. C. (2011). The Dynamic Nature of Autophagy in Cancer. *Genes & Development.* 25(19). pp.1999–2010.
- Kondo, Y., Kanzawa, T., Sawaya, R., Kondo, S. (2005). The Role of Autophagy in Cancer Development and Response to Therapy. *Nat. Rev. Cancer.* 5(9). pp.726–734.
- Kumar, V., Cotran, R. S., Robbins, S. L. (2003). *Robbins Basic Pathology.* 7th ed. New York: Elsevier.

- Levine, B. & Klionsky, D.J. (2004). Development by Self-digestion: Molecular Mechanisms and Biological Functions of Autophagy. *Dev. Cell.* 6(4). 463–77.
- Levine, B. & Abrams, J. (2008). p53: The Janus of Autophagy? *Nat. Cell. Biol.* 10(6). pp.637–639.
- Ma, B., Shan, M., Sun, G., Ren, G., Dong, C., Yao, X., *et al.* (2015). Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer. *Mol. Med. Rep.* 12, 5246-5254.
- Mathew, R., Karantza-Wadsworth, V., White, E. (2007). Role of autophagy in cancer. *Nature reviews. Cancer.* 7(12). pp.961–967.
- Menon, S. & Manning, B. D. (2008). Common Corruption of the mTOR Signaling Network in Human Tumors Oncogene. 27(02). S43–S51.
- Mizushima, N. (2007). Autophagy: Process and Function. *Genes Dev.* 21. pp.2861–2873.
- Moore, K. L., Dalley, A. F., Agur, A. M. (2010). Clinically Oriented Anatomy. 6rd edition. Philadelphia: Wolters Kluwer.
- Mutee, A. F., Kaur, G., Kumar, G., Sifzizul, T., Khalid, I. A., Tan, M. L. (2009). Immunohistochemical Evaluation of mTOR and Beclin-1 Protein Expression in Human Breast Cancer and Adjacent Normal Tissues, A Study in Malaysian Patient. *Bentham Op.* 3: 111-112.
- Narita, M. & Inoki, K. (2012). Rags Connect mTOR and autophagy: Small GTPases 3. pp.111–114
- Panduan Penatalaksanaan Kanker Payudara. (2014). Pedoman Penatalaksanaan Kanker Solid. PERABOI.
- Pattingre, S., Bauvy, C., Codogno, P. (2003). Amino Acids Interfere with the ERK1/2-dependent Control of Macroautophagy by Controlling the Activation of Raf-1 in Human Colon Cancer HT-29 Cells. *J. Biol. Chem.* 278: 16667–16674.
- Pattingre, S., Espert, L., Biard-Piechazyk, M., Codogno, P. (2008). Regulation of Macro autophagy by mTOR and Beclin 1 Complexes. *J. Biol. Chem.* 90: 313-323.

Richard, L. Drake, Wayne, V., Adam, W. M. (2009). *Gray's Anatomy for Student*. 2<sup>nd</sup> ed. Churchill Livingstone: Elsevier.

Rouschop, K.M. & Wouters, B.G. (2009). Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways. *Curr. Mol. Med.* 9:417–424.

Ueng, S.-H., Chen, S.-C., Chang, Y.-S., Hsueh, S., Lin, Y.-C., Chien, H.-P., et al. (2012). Phosphorylated mTOR Expression Correlates with Poor Outcome in Early-stage Triple Negative Breast Carcinomas. *Int. J. Clin. Exp. Pathol.* 5:806–813.

Walsh, S., Flanagan, L., Quinn, C., Evoy, D., Mcdermott, E. W., Pierce, A., et al. (2012). mTOR in Breast Cancer: Differential Expression in Triple-negative and Non-triple-negative Tumors. *Breast.* 21(2). pp.178–182.

Wang, H. G. (2003). *Autophagy and Cancer*. 1st ed. New York: Springer..

White, E. J., Martin, V., Liu, J.-L., Klein, S. R., Piya, S., Gomez-Manzano, et al. (2011). Autophagy Regulation in Cancer Development and Therapy. *Am. J. Cancer Res.* 1(3). pp. 362–372.

World Health Organization. (2014). *Cancer Country Profiles*. pp.22–23.

Yang, Z. & Klionsky, D. J. (2009). An Overview of the Molecular Mechanism of Autophagy. *Current Topics in Microbiology and Immunology*. pp.1–32.

Yang, Z., Chee, C.E., Huang, S., Sinicrope, F.A. (2011). The Role of Autophagy in Cancer: Therapeutic Implications. *Molecular Cancer Therapeutics.* 10(9). pp.1533–1541.

Youssef, N.S., Hewedi, I.H., Raboh, N.M. (2008). Immunohistochemical Expression of Survivin in Breast Carcinoma: Relationship with Clinicopathological Parameters, Proliferation and Molecular Classification. *J. Egypt Natl. Canc. Inst.* 20:348–357.

Zhou, X., Tan, M., Stone-Hawthorne, V., Klos, K.S., Lan, K.H., Yang, Y., et al. (2004). Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. *Clin. Cancer. Res.*10(20):6779–88.